Aradigm Corporation (NASDAQ: ARDM) today announced that Defence R&D Canada (DRDC) has extended the development program for the aerosolized delivery of liposome-encapsulated ciprofloxacin as a treatment for bioterror-related anthrax.
Aradigm Corporation (NASDAQ: ARDM) today announced that Defence R&D Canada (DRDC) has extended the development program for the aerosolized delivery of liposome-encapsulated ciprofloxacin as a treatment for bioterror-related anthrax.